Ovarian Cancer Awareness Month: Why 2026 Is a Pivotal Year for Research Funding
Every March, teal shows up. On lapel pins, on ribbons, on the profile pictures of women who have been through something they never asked for. Ovarian Cancer Awareness Month rolls around, and for thirty-one days a disease that usually goes unmentioned gets said out loud.
Awareness months can feel a little abstract — a hashtag, a ribbon, a week of posts and then back to normal. So this year we want to make the case that March 2026 is different, and to show you the numbers that make us believe it.
What happened at Westminster
On Wednesday, March 18, advocates from Target Ovarian Cancer went to Parliament. Not to hold a bake sale. To sit in front of the people who decide where research money goes and make them look at the problem directly.
The UK has an All-Party Parliamentary Group on Ovarian Cancer — a standing group of MPs and peers from across the political spectrum who meet through the year specifically about this disease, with Target Ovarian Cancer providing its staffing and research. That structure exists because someone, years ago, refused to let ovarian cancer be a footnote in a general cancer conversation.
The statistic they carried into that room is one you don’t easily shake off: in the UK in 2026, a woman dies of ovarian cancer every two hours. It is the sixth most common cancer in British women, and it has one of the lowest five-year survival rates of any common cancer.
In the United States, the picture rhymes. More than 21,000 women are diagnosed each year, and more than 12,450 die. Most are found after the cancer has already spread beyond the ovaries, because the early symptoms — bloating, feeling full quickly, pelvic pressure, needing the bathroom more often — are the same symptoms almost every woman has occasionally had for entirely ordinary reasons. There is still no reliable screening test. No mammogram equivalent. No Pap smear equivalent.
That combination — vague symptoms, no screening, late diagnosis — is why awareness is not a soft, decorative thing. Right now, a woman’s own attention to her own body is the earliest detection system medicine has to offer her. If you want the short version to share with someone you love, our guide to the signs and symptoms of ovarian cancer is written for exactly that.
Now here’s the part that made us sit up
While advocates were making the case for more research, the research world quietly delivered a number that suggests the case is already landing.
According to GlobalData, 29 Phase III ovarian cancer trials launched in 2025 — nearly double the number launched in 2024, and 26% higher than the previous record year. By early 2026, new trial launches had already passed the total for all of 2023. Right now there are 86 Phase III trials running worldwide, with 28 more in planning.
We should explain why that’s a big deal, because “Phase III” is jargon.
Drug testing happens in stages, and each stage is more expensive and more committed than the last:
- Phase I asks: is this safe, and what’s the right dose? A small number of volunteers.
- Phase II asks: does it actually seem to work? A few dozen to a few hundred.
- Phase III asks: is it better than what we already have? Hundreds to thousands of participants, multiple countries, years of follow-up, and a price tag that runs into the hundreds of millions.
Nobody launches a Phase III trial casually. It is the stage where a company or a research consortium says we believe in this enough to bet the farm. So twenty-nine of them in a single year isn’t just activity. It’s confidence. It means a lot of people with a lot of money looked at the early data in ovarian cancer and concluded that something is finally working.
Why the surge is happening now
Two forces are behind it.
The first is that recent approvals proved the field can win. Pembrolizumab plus paclitaxel was approved in February for platinum-resistant disease. Before that, mirvetuximab was approved for women whose tumors carry high levels of a protein called folate receptor alpha. Success attracts investment the way nothing else does.
The second force is the gap those wins left behind. Mirvetuximab is only approved for women whose tumors are “FRα-high” — meaning at least 75% of the tumor cells show moderate-to-strong staining for folate receptor alpha on a lab test. Clear that bar and you have a genuinely effective option. Fall below it and the drug isn’t for you, however much of the receptor your tumor carries.
That is the shape of the whole problem right now: every recent win helps a defined slice of women, and everyone outside the slice is still waiting. Closing those gaps is precisely what the new wave of trials is chasing, with antibody-drug conjugates, immune checkpoint inhibitors, oncolytic viruses (viruses engineered to infect and burst cancer cells while leaving healthy ones alone), and biomarker-guided strategies that try to match each woman to the drug her particular tumor is vulnerable to.
The unglamorous obstacles
Running these trials globally is harder than it sounds, and the obstacles are worth naming because they’re the kind that money and advocacy can actually fix.
Care isn’t the same everywhere. In many lower- and middle-income countries, women don’t have access to modern maintenance therapies or genetic testing at all. When “standard treatment” means different things in different countries, comparing a new drug against it gets complicated fast.
The tests aren’t the same everywhere either. Biomarker testing — the lab work that determines whether your tumor has PD-L1, or folate receptor alpha, or a BRCA mutation — is inconsistent across regions. Some countries prohibit shipping tissue samples abroad, so a trial can’t simply send everything to one central lab.
Precision medicine makes enrollment harder. The more specific a drug’s target, the fewer eligible patients there are, and the more hospitals you need to find them. It’s the paradox of targeted therapy: better science, harder recruiting.
None of these are scientific problems. They’re infrastructure and policy problems — which is exactly what advocates in rooms like Westminster are there to push on.
What you can actually do
Awareness month works when awareness turns into something. A few things that genuinely help:
Learn the symptoms and tell one person. Not a lecture. Just: hey, if bloating or feeling full fast sticks around for more than a couple of weeks, that’s worth a doctor’s appointment. Most women have never been told this.
Ask about trials — for yourself or someone you’re supporting. A quarter of the progress in this article exists because someone enrolled. Trials aren’t a last resort; increasingly they’re where the best available treatment lives.
Speak up where decisions get made. Research funding follows political attention, and political attention follows constituents who write, call, and show up. If you’d like to help with that, our get involved page is where to start.
Support the research. Every one of those 29 trials started as a hypothesis someone had to fund before anyone knew it would work.
The thing worth holding onto
For a long time, ovarian cancer research was a story of patience — good scientists working on a hard problem with too little money and too few trials.
Twenty-nine Phase III trials in a year is what the other side of that looks like. Not a cure. Not yet. But a field that has stopped inching and started moving, with real momentum behind it and real drugs in the pipeline behind that.
Teal ribbons don’t cure anything. But they got the door open, and this year there’s something walking through it.
Sources